Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) said it will report second-quarter 2026 financial results on Aug. 5, 2026 after market close. The company plans a 4:30 PM ET conference call and webcast, with a replay available from 8:30 PM ET Aug. 5 through Aug. 12. Investors can access materials via Vanda’s website.
How this was made
The 30-second read
Why it matters
The main tradable element is timing. The market reaction will depend on the Q2 print and any guidance or corporate updates delivered on the call, which are not included in this notice.
Market read
Provides a concrete earnings event date and call timing for VNDA, enabling event-driven positioning and hedging.
What to watch
Traders should focus on what management typically emphasizes in these calls (pipeline updates, payer dynamics, and guidance), but this article does not disclose any of those specifics.
Background
The company announces its schedule for releasing second-quarter 2026 results and hosting a conference call, including replay availability.
Ticker impact
Vanda Pharmaceuticals will release Q2 2026 financial results on Aug 5 after the market closes, with a scheduled conference call that day.
Likely elevated pre-earnings volatility and post-close reaction on Aug 5 once results are released.
The article provides the exact release date and call timing but no financial figures, guidance, or new operational/regulatory developments.
Market effects
Biopharma names with upcoming earnings can see sector-wide risk-on or risk-off positioning, but no sector-specific datapoint is provided here.
Primarily US-focused trading around Nasdaq-listed VNDA; no broader regional macro linkage is stated.
No global regulatory, trial, or commercial event is mentioned, so global spillover is limited.
Counterpoint
Because the release date is already known to the market via standard investor relations calendars, the incremental trading edge may be small unless positioning is thin or expectations are unusually polarized.
Key entities
- companyVanda Pharmaceuticals Inc.
Nasdaq-listed biopharmaceutical company scheduling Q2 2026 results for Aug 5, 2026 after the market closes.
- tickerVNDA
Vanda Pharmaceuticals stock ticker referenced in the announcement.